The nilotinib trial has enrolled 65 patients with a dose of 400 mg twice daily produce complete cytogenetic response in 50 of 51 patients (98 %) followed for at least three months. Major molecular response was achieved in 32 patients (63 %) with 12 (24 %), achieving complete molecular response.CML is caused by an abnormality known as the Philadelphia chromosome that produces aberrant protein, Bcr-Abl, which causes overproduction of a type of white blood cells that causes the disease. These three drugs are tyrosine kinase inhibitors, which block the action of Bcr-Abl. Dasatinib and nilotinib target multiple variants of the protein, and often after work, imatinib has failed. Both are approved by the Food and Drug Administration for patients who can not tolerate imatinib or CML that is resistant to the drug.
The researchers left arm twice a day of the trial, maintaining the 100 mg once a day with open arms, because he has produced high rates of major molecular response with fewer side effects.
Month therapyPercent patients with complete cytogenetic response
Co-authors of the study are dasatinib Ravanda Farhad, MD, Charles Koller, MD, Walker and Brenda O’Brien, Borthakur, Jabbour, Shan and Kantarjian Department of Leukemia and Hematopathology Jones.
Complete cytogenetic response is the absence of chromosome defect that causes the disease.
Two drugs approved as a treatment for chronic myeloid leukemia resistant strains will continue to provide patients with faster, better response as the first treatment that current first-line drugs, researchers at the University of Texas MD Anderson Cancer Center reported at the 51 st Meeting Annual American Society of Hematology.
(Number of patients precious) DasatinibImatinib 400mgImatinib 800mg 3903763 6965485 12976589 18936789 24936788 30926789
‘More patients treated with nilotinib or dasatinib are achieving a complete response should be faster than two daily doses of imatinib,’ said Jorge Cortes, MD, Professor, Department of Leukemia MD Anderson and Chief two studies.
The initial treatment for CML remains imatinib, a drug known as Gleevec by Novartis, which has increased the survival rate at five years for the disease by 50 % to 90 % of patients. In specific clinical trials, MD Anderson researchers are comparing nilotinib, a drug known as Tasigna, Novartis, and dasatinib, a Bristol-Myers Squibb drug known as Sprycel, historical results of previous studies of imatinib.
All patients in both studies are alive, and the recording continues. Side effects are closely monitored and some patients in each trial had their treatment reduced or temporarily interrupted because of toxicity. Side effects were manageable and similar to those observed for imatinib, Cortes said.
Months in patients with complete cytogenetic response therapyPercent DasatinibImatinib 400mgImatinib 800mg 3823763 6945485 12986589 18896789 24846788 30836789